OTCMKTS:KHTRF - Knight Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.51
  • Forecasted Upside: 55.80 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.18
+0.30 (1.20%)

This chart shows the closing price for KHTRF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Knight Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KHTRF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KHTRF

Analyst Price Target is $6.51
▲ +55.80% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Knight Therapeutics in the last 3 months. The average price target is $6.51, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 55.80% upside from the last price of $4.18.

This chart shows the closing price for KHTRF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Knight Therapeutics. This rating has held steady since November 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/27/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/25/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/13/2022Knight EquityLower Price TargetC$7.00 ➝ C$6.75
3/25/2022Raymond JamesLower Price TargetC$8.50 ➝ C$7.50
3/25/2022Knight EquityLower Price TargetC$8.00 ➝ C$7.00
3/25/2022Stifel NicolausDowngradeBuy ➝ HoldC$7.00 ➝ C$5.30
11/15/2021Stifel NicolausBoost Price TargetBuyC$6.50 ➝ C$7.00
9/23/2021Stifel EuropeUpgradeHold ➝ BuyC$5.95 ➝ C$6.50
4/26/2021KCGBoost Price TargetOutperform$6.75 ➝ $7.75
4/26/2021Cannonball ResearchReiterated RatingBuy
4/26/2021Raymond JamesReiterated RatingOutperform
4/26/2021Knight EquityBoost Price TargetOutperform$6.75 ➝ $7.75
11/16/2020KCGLower Price TargetOutperform$8.25 ➝ $6.75
11/16/2020Knight EquityLower Price TargetOutperform$8.25 ➝ $6.75
8/13/2020Stifel NicolausInitiated CoverageBuy$10.50
6/23/2020Stifel NicolausReiterated RatingBuy$10.50
10/9/2019Raymond JamesSet Price TargetBuy$10.30
4/5/2019Paradigm CapitalReiterated RatingHold
1/16/2019Raymond JamesReiterated RatingBuy
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/26/2022

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Knight Therapeutics logo
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
Read More

Today's Range

Now: $4.18
Low: $4.18
High: $4.18

50 Day Range

MA: $4.18
Low: $4.05
High: $4.45

52 Week Range

Now: $4.18
Low: $3.66
High: $4.51

Volume

N/A

Average Volume

1,455 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Knight Therapeutics?

The following equities research analysts have issued reports on Knight Therapeutics in the last twelve months: Knight Equity, Raymond James, Stifel Europe, and Stifel Nicolaus.
View the latest analyst ratings for KHTRF.

What is the current price target for Knight Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Knight Therapeutics in the last year. Their average twelve-month price target is $6.51, suggesting a possible upside of 55.8%.
View the latest price targets for KHTRF.

What is the current consensus analyst rating for Knight Therapeutics?

Knight Therapeutics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KHTRF will outperform the market and that investors should add to their positions of Knight Therapeutics.
View the latest ratings for KHTRF.

How do I contact Knight Therapeutics' investor relations team?

Knight Therapeutics' physical mailing address is 3400 de Maisonneuve West, Montréal, QC H3Z. The company's listed phone number is (514) 484-4483. The official website for Knight Therapeutics is www.gud-knight.com. Learn More about contacing Knight Therapeutics investor relations.